Date: 2016-04-25
Type of information: Nomination
Compound:
Company: Epizyme (USA - MA)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details: * On April 24, 2016, Epizyme announced that it has expanded its executive leadership team with the addition of Susan Graf , who joins the company as Chief Business Officer. Ms. Graf will report directly to Epizyme's President and Chief Executive Officer, Robert Bazemore . Additionally, over the last quarter, Jeannie Chu joined the company as Vice President of Program and Portfolio Management and Michael Boretti joined as Vice President of Business Development.
As Epizyme's first Chief Business Officer, Susan Graf will oversee and direct the implementation of Epizyme's new corporate strategy and lead corporate and business development and alliance management. She was most recently Vice President, Corporate Development and Strategy for NPS Pharma before it was acquired by Shire in 2015. She was intimately involved in the company's sale to Shire, in addition to serving on the executive team that transformed NPS Pharma into a global, commercial-stage, rare-disease biopharmaceutical company. Prior to NPS Pharma, Susan Graf spent nearly 18 years at Roche in a number of leadership and executive positions in business development, commercial assessment, due diligence, mergers & acquisitions, marketing, market research, sales and manufacturing. Ms. Graf was recognized as a Healthcare Businesswomen's Association Rising Star in 2011 and has been named to Purdue University's '40 Under 40' list.
Jeannie Chu joined Epizyme in February 2016 as Vice President of Program and Portfolio Management. In this role, Jeannie has begun to create structured, cross-functional project teams to oversee the development and commercialization of tazemetostat, as well as development of Epizyme's portfolio of epigenetic products. Prior to Epizyme , Jeannie held roles of increasing responsibility at Biogen, most recently as Senior Director of Program Leadership and Management. During her 11-year tenure at Biogen, she served as Program Director and led the development teams for the nusinersen, Zinbryta™, lixivaptan, and Tysabri® programs. She was also Director of the Emerging Markets Commercial group. Jeannie holds an M.B.A. from the STERN School of Business at New York University .
Michael Boretti joined Epizyme as Vice President of Business Development in March 2016 . In this role, Michael has already begun to lead new partnering opportunities, as well as ongoing alliances. Prior to Epizyme , Michael worked in roles of increasing responsibility at AVEO Oncology from 2008 to March 2016 , most recently serving as Vice President, Corporate Development and Alliance Management. Prior to joining AVEO, Michael was a consultant in the life sciences practice at L.E.K. Consulting , a global strategy consulting firm. Michael received his Ph.D. in bioengineering from the University of Pennsylvania .
Financial terms:
Latest news:
